Regeneron Pharmaceuticals (REGN) Gets EU Backing For Easier Dosing And 84 Week Trial Data

• Regeneron Pharmaceuticals (NasdaqGS:REGN) received a positive opinion from the EMA’s CHMP for a new Libtayo dosing schedule across all approved uses.
• The CHMP-backed regimen is designed to offer a more convenient dosing option that may reduce time spent in treatment settings.
• Regeneron also reported 84-week efficacy and safety data for Pasatru from the long-term Phase 3 OPTIMA trial in fibrodysplasia ossificans progressiva.
• The fresh Libtayo dosing opinion and long-term Pasatru data are only part of the broader Regeneron story. Check out 2 other big wins that Regeneron Pharmaceuticals investors should know about.

Consider exploring other healthcare and biotech stocks that are also working on AI-enabled therapies and drug platforms through 34 healthcare AI stocks.

Regeneron Pharmaceuticals operates as a large US biotech focused on discovering and commercializing medicines across multiple disease areas. Expanded flexibility for Libtayo and longer-term data for Pasatru both speak directly to how its research pipeline translates into real-world treatment options for patients.

Does the team leading Regeneron Pharmaceuticals have what it takes? See our full breakdown of the management team's track record and compensation.

How might the new Libtayo dosing schedule matter for Regeneron Pharmaceuticals?

The CHMP support for a 700 mg every six weeks Libtayo regimen, after an initial 12 weeks of 350 mg every three weeks, points to a more flexible treatment pattern across all approved uses. Shorter 15 to 30 minute infusions for 350 mg could also make the therapy easier to fit into busy oncology clinics, which can influence uptake and persistence.

Does this news change the current Regeneron Pharmaceuticals Narrative?

The Narrative leans on a broader late stage pipeline in oncology and rare disease to support long term earnings power, alongside Dupixent and EYLEA HD. Longer term Pasatru data in fibrodysplasia ossificans progressiva and a more convenient Libtayo schedule both reinforce that storyline of new indications and rare disease launches contributing additional revenue streams over time.

See how these catalysts shape Regeneron Pharmaceuticals' path to a $851 fair value.

What should investors watch next from these Regeneron updates?

Two signposts matter most from here: the formal EMA decision on the expanded Libtayo dosing schedule following the October 2026 CHMP opinion, and the planned start of the OPTIMA 2 Phase 3 trial in adolescents and children with FOP later in 2026. Together these developments will show how quickly Regeneron can broaden both Libtayo usage and Pasatru’s addressable population.

One more thing about Regeneron Pharmaceuticals that investors should not ignore

Everything hinges on what the stream of future cash coming out of Regeneron Pharmaceuticals suggests the whole business might reasonably be worth compared with the current share price. Find out exactly what Regeneron Pharmaceuticals is worth today based on its cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com